Biogen and the desperation of a need for Alzheimer's drugs

Biogen biologics plant in Denmark
(Biogen)

Biogen is set to provoke an early pointer of the direction the FDA will take under new Commissioner Stephen Hahn. Having made the shock decision to resurrect aducanumab after it failed a phase 3 futility analysis, Biogen is set to file for FDA approval of the Alzheimer’s disease drug next year.

The submission will be a test of how far Hahn’s FDA is willing to diverge from its established approval standards. Under U.S. law, companies need to show “substantial” evidence of effectiveness to win approval. Biogen will arrive at the FDA with results from one trial that suggest aducanumab is no better than placebo and data from another that link it to improved scores on a dementia scale.

Biogen and some physicians think the overall data set shows aducanumab works. Many analysts are more skeptical, arguing that Biogen’s data, which even its supporters admit are complex, are too weak to constitute “substantial” evidence.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Under Hahn’s predecessor, the FDA approved drugs on the basis of evidence that many outsiders saw as insubstantial, but those products typically targeted rare diseases. Alzheimer’s is on a different scale entirely. Other companies will be closely watching how Hahn’s FDA handles the chance to finally get a new treatment to Alzheimer’s patients.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.